As research into medical cannabis expands, health professionals and families are asking how safety and outcomes are monitored, particularly in people living with dementia. While the UK allows specialist prescribing of cannabis-based medicinal products (CBPMs), there are no dementia-specific monitoring protocols yet approved by NICE or NHS England. However, broader safety frameworks for controlled medicines do apply.
Current Clinical Oversight
Under the Misuse of Drugs Regulations 2001, all cannabis-based products are Schedule 2 controlled drugs. This means any prescription, storage, and administration must follow strict NHS and CQC oversight procedures (NHS England, 2023).
Specialist doctors listed on the General Medical Council’s Specialist Register are the only clinicians legally authorised to prescribe these medicines. For dementia, all use is considered off-label and must involve ongoing clinical review.
General Safety Monitoring Standards
Although NICE has not published dementia-specific protocols, safety monitoring follows existing frameworks for controlled or psychoactive medicines. According to NICE NG144 and NICE SC1, care teams must:
- Record all doses on a Medication Administration Record (MAR).
- Monitor for sedation, confusion, agitation, and falls.
- Documents change in mood, sleep, appetite, and pain response.
- Report any suspected side effects to the Yellow Card Scheme via the MHRA.
These measures form the basis of outcome tracking when cannabis is prescribed in specialist dementia research or symptom management programmes.
Role Of the CQC And Clinical Ethics
The Care Quality Commission (CQC) oversees controlled drugs management across all registered care settings. Its Controlled Drugs Annual Report 2024 highlights the need for robust audit trails, staff training, and clear reporting lines to local Controlled Drugs Accountable Officers (CDAOs).
Ethically, monitoring must comply with the Mental Capacity Act 2005, ensuring decisions about continued cannabis use reflect best-interest discussions and informed consent. The Alzheimer’s Society emphasises that families and carers should be involved in evaluating behavioural and quality-of-life outcomes.
Research Monitoring Initiatives
The STAND trial at King’s College London, supported by Alzheimer’s Research UK, is currently evaluating Sativex (1:1 THC: CBD) for agitation in dementia. Participants undergo structured monitoring for cognitive change, sleep, and safety, which may inform future national guidance.
Clinical Bottom Line
- No national dementia-specific cannabis monitoring protocols exist.
- General controlled-drug and NICE SC1 procedures apply to all CBPM use.
- Continuous review and MAR documentation are mandatory.
- Clinical outcomes should include cognition, mobility, and behaviour tracking.
Educational Context: AlleviMed
AlleviMed provides educational resources explaining how clinicians monitor safety and outcomes when prescribing medical cannabis under UK regulation. It promotes best practice in documentation, communication, and ethical oversight.
Takeaway
Cannabis use in dementia requires individualised monitoring, not standard protocols. Until NICE issues dementia-specific guidance, care teams must rely on existing controlled-drug frameworks, specialist supervision, and person-centred observation to safeguard outcomes and wellbeing.
